



Special Issue Reprint

# Selected Papers from CUBANNI 2017—"The Fourth International Workshop of Neuroimmunology"

www.mdpi.com/books/reprint/1121

Edited by Maria De los Angeles Robinson Agramonte Carlos Alberto Gonçalves Dario Siniscalco

ISBN 978-3-03897-487-1 (Softback) ISBN 978-3-03897-488-8 (PDF)



In parallel with a decrease/stabilization in the use of internationally controlled drugs, the market of novel psychoactive substances (NPS) continues increasing, year after year, with the Internet playing a pivotal role in contributing to this complex scenario. At times, although misleading, the terms 'legal highs' or 'research chemicals' have been used to describe these molecules. Overall, about 5% of 19-24-year-old European people have already experimented with them, because both NPS' intense psychoactive effects and their virtual nondetectability in routine drug screenings. Although 'novel' typically refers to molecules that have recently become a reason of current/potential public health concern, at times, the NPS scenario may indeed focus on pharmaceutical molecules. These may have either not entered the market, or are currently prescribed, with their potential for misuse resulting from the relating high dosages/idiosyncratic ways of self-administration. A concurrent use of a range of different NPS, and/or medications, is frequently being reported and this may be a reason of further clinical complications. Given their complex pharmacodynamics, there are increasing levels of concern about the onset of acute/chronic psychopathological associated with NPS intake. This Special Issue aims at providing an overview of a range of NPS-related issues, e.g., preclinical, epidemiological, and clinical pharmacological; the medical and psychopathological consequences associated with their intake; and, finally, the analytical chemistry and forensic analysis challenges associated with the NPS phenomenon.



Order Your Print Copy You can order print copies at www.mdpi.com/books/reprint/1121

# **MDPIN**Books Publishing Open Access Books & Series

MDPI Books offers quality open access book publishing to promote the exchange of ideas and knowledge in a globalized world. MDPI Books encompasses all the benefits of open access - high availability and visibility, as well as wide and rapid dissemination. With MDPI Books, you can complement the digital version of your work with a high quality printed counterpart.



# **Open Access**

Your scholarly work is accessible worldwide without any restrictions. All authors retain the copyright for their work distributed under the terms of the Creative Commons Attribution License



#### **Author Focus**

Authors and editors profit from MDPI's over two decades of experience in open access publishing, our customized personal support throughout the entire publication process, and competitive processing charges as well as unique contributor discounts on book purchases.



#### **High Quality & Rapid Publication**

MDPI ensures a thorough review for all published items and provides a fast publication procedure. State-of-the-art research and time-sensitive topics are released with a minimum amount of delay.



# **High Visibility**

Due to our global network and well-known channel partners, we ensure maximum visibility and broad dissemination. Title information of books is sent to international indexing databases and archives, such as the Directory of Open Access Books (DOAB), and the Verzeichnis Lieferbarer Bücher (VLB).



# **Print on Demand and Multiple Formats**

MDPI Books are available for purchase and to read online at any time. Our print-on-demand service offers a sustainable, cost-effective and fast way to publish MDPI Books printed versions.

MDPI AG St. Alban-Anlage 66 4052 Basel Switzerland Tel: +41 61 683 77 34 www.mdpi.com/books books@mdpi.com

